MORRIS PLAINS, N.J., Feb. 14, 2025 (GLOBE NEWSWIRE) — Ensho Therapeutics, Inc., a privately held, clinical-stage biopharmaceutical company focused on developing breakthrough oral therapies for patients with inflammatory diseases, announced today that additional analyses from the Phase 1 development of its lead drug candidate, NSHO-101, will be presented at the 20th congress of the European Crohn’s and Colitis Organisation (ECCO 2025) being held February 19 to 22, 2025, in Berlin, Germany.
Presentation Details:
Title: Oral α4β7 integrin antagonist EA1080 (NSHO-101) demonstrates target engagement and α4β7 integrin receptor occupancy following once-daily administration in healthy volunteers (abstract number EC25-1417)
Authors: B G Feagan; Y Yazawa; T Seki; E Watanabe; H Ohishi; H Ueo; C Saito; U Lorch
Session Name: Guided Poster Session
Session Date and Time: Friday, February 21, 12:40-13:40 CET
Location: CityCube Messe Berlin, Poster Exhibition, Hall 2.2
Poster #: P0815
About NSHO-101 (also known as EA1080)
NSHO-101 is a novel, oral, selective α4β7 integrin inhibitor being developed for the potential treatment of patients with IBD. α4β7 is a cell surface receptor that helps regulate the migration of immune cells to the intestine and plays a key role in controlling inflammatory responses. It binds to mucosal addressin cell adhesion molecule-1 (MAdCAM-1), which is expressed on high endothelial venules in the intestine and is upregulated in response to inflammation. By blocking this interaction, NSHO-101 offers the potential to prevent the adhesion and migration of inflammatory leukocytes into the intestine, thereby reducing inflammation and improving symptoms in inflammatory bowel disease (IBD).
The Phase 1 clinical program for NSHO-101 assessed the safety, tolerability, food effects, pharmacokinetic (PK) and pharmacodynamic (PD) of single and multiple ascending doses of NSHO-101 in 184 healthy volunteers. NSHO-101 demonstrated target engagement in this Phase 1 program. NSHO-101 was generally safe and well tolerated. Ensho plans to initiate Phase 2 clinical development of NSHO-101 as a potential treatment for ulcerative colitis (UC) in the first half of 2025.
About Ensho Therapeutics, Inc.
Ensho Therapeutics, Inc. is a privately held, clinical-stage biopharmaceutical company focused on developing breakthrough oral therapies for patients with inflammatory diseases. The company’s initial focus is on a pipeline of oral, selective small molecule inhibitors of lymphocyte homing integrin α4β7 for inflammatory bowel disease (IBD), a mechanism already validated by a commercially available antibody. Ensho’s assets were acquired from EA Pharma Co., Ltd., a subsidiary of Eisai Co., Ltd., that is focused on gastrointestinal disease. Ensho is preparing to initiate a Phase 2 clinical program of NSHO-101, the lead asset in the company’s pipeline, as a potential treatment for ulcerative colitis (UC). For additional information on Ensho Therapeutics, Inc., please visit www.enshorx.com.
Contacts:
Media:
Aljanae Reynolds
areynolds@wheelhouselsa.com
Investors:
info@enshorx.com
After President Trump's Marijuana Executive Order, Will the DEA Act-or Be Compelled by the Courts?"Despite…
Boards and executive buyers are raising the 2026 bar for all product and service rankings…
Boards and executive buyers are raising the 2026 bar for all product and service rankings…
Tampa based Celebrity Board-Certified Plastic Surgeon Dr. Meegan Gruber expands an interactive approach that allows…
Clemson University and Nordic Wellness have launched a pioneering partnership tackling the student mental health…
Telehealth Platform Offers Compounded GLP-1 Injections and Oral Tablets at $299/Month With No Contract as…